首页> 美国卫生研究院文献>Journal of Bacteriology >Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance.
【2h】

Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance.

机译:肺炎链球菌编码DNA拓扑异构酶IV的parC和parE基因的克隆和鉴定:在氟喹诺酮耐药性中的作用。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

DNA topoisomerase IV mediates chromosome segregation and is a potential target for antibacterial agents including new antipneumococcal fluoroquinolones. We have used hybridization to a Staphylococcus aureus gyrB probe in concert with chromosome walking to isolate the Streptococcus pneumoniae parE-parC locus, lying downstream of a putative new insertion sequence and encoding 647-residue ParE and 823-residue ParC subunits of DNA topoisomerase IV. These proteins exhibited greatest homology respectively to the GrlB (ParE) and GrlA (ParC) subunits of S. aureus DNA topoisomerase IV. When combined, whole-cell extracts of Escherichia coli strains expressing S. pneumoniae ParC or ParE proteins reconstituted a salt-insensitive ATP-dependent decatenase activity characteristic of DNA topoisomerase IV. A second gyrB homolog isolated from S. pneumoniae encoded a 648-residue protein which we identified as GyrB through its close homology both to counterparts in S. aureus and Bacillus subtilis and to the product of the S. pneumoniae nov-1 gene that confers novobiocin resistance. gyrB was not closely linked to gyrA. To examine the role of DNA topoisomerase IV in fluoroquinolone action and resistance in S. pneumoniae, we isolated mutant strains stepwise selected for resistance to increasing concentrations of ciprofloxacin. We analysed four low-level resistant mutants and showed that Ser-79 of ParC, equivalent to resistance hotspots Ser-80 of GrlA and Ser-84 of GyrA in S. aureus, was in each case substituted with Tyr. These results suggest that DNA topoisomerase IV is an important target for fluoroquinolones in S. pneumoniae and establish this organism as a useful gram-positive system for resistance studies.
机译:DNA拓扑异构酶IV介导染色体分离,是包括新的抗肺炎球菌氟喹诺酮在内的抗菌剂的潜在靶标。我们已经使用了与金黄色葡萄球菌gyrB探针的杂交以及染色体行走的方法来分离肺炎链球菌parE-parC基因座,该基因座位于推定的新插入序列的下游,编码DNA拓扑异构酶IV的647残基ParE和823残基ParC亚基。这些蛋白质分别显示出与金黄色葡萄球菌DNA拓扑异构酶IV的GrlB(ParE)和GrlA(ParC)亚基最大的同源性。合并后,表达肺炎链球菌ParC或ParE蛋白的大肠杆菌菌株的全细胞提取物可重建DNA拓扑异构酶IV特有的盐不敏感的ATP依赖性脱氢酶活性。从肺炎链球菌分离的第二个gyrB同源物编码一个648个残基的蛋白质,我们通过与金黄色葡萄球菌和枯草芽孢杆菌的对应物以及赋予新生物素的肺炎链球菌nov-1基因的产物紧密同源性,将其鉴定为GyrB。抵抗性。 GyrB与gyrA没有紧密联系。为了检查DNA拓扑异构酶IV在肺炎链球菌中氟喹诺酮作用和抗药性中的作用,我们分步选择了对环丙沙星浓度增加有抗性的突变菌株。我们分析了四个低水平的抗性突变体,并显示在每种情况下均用Tyr替代了ParC的Ser-79(相当于GrlA的抗性热点Ser-80和GyrA的Ser-84)。这些结果表明,DNA拓扑异构酶IV是肺炎链球菌中氟喹诺酮类的重要靶标,并将该生物体确立为耐药性研究的有用的革兰氏阳性系统。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号